Skip to main content
Top
Published in: Clinical & Experimental Metastasis 8/2011

01-12-2011 | Research Paper

Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10

Authors: Florian Schelter, Martina Grandl, Bastian Seubert, Susanne Schaten, Stephanie Hauser, Michael Gerg, Carla Boccaccio, Paolo Comoglio, Achim Krüger

Published in: Clinical & Experimental Metastasis | Issue 8/2011

Login to get access

Abstract

In many different tumor entities, increased expression of tissue inhibitor of metalloproteinases-1 (Timp-1) is associated with poor prognosis. We previously reported in mouse models that elevated systemic levels of Timp-1 induce a gene expression signature in the liver microenvironment increasing the susceptibility of this organ to tumor cells. This host effect was dependent on increased activity of the hepatocyte growth factor (Hgf)/hepatocyte growth factor receptor (Met) signaling pathway. In a recent study we showed that Met signaling is regulated by Timp-1 as it inhibits the Met sheddase A disintegrin and metalloproteinase-10 (Adam-10). The aim of the present study was to elucidate whether the metastatic potential of tumor cells benefits from autocrine Timp-1 as well and involves Adam-10 and Met signaling. In a syngeneic murine model of experimental liver metastasis Timp-1 expression and Met signaling were localized within metastatic colonies and expressed by tumor cells. Knock down of tumor cell Timp-1 suppressed Met signaling in metastases and inhibited metastasis formation and tumor cell-scattering in the liver. In vitro, knock down of tumor cell Timp-1 prevented Hgf-induced Met phosphorylation. Consequently, knock down of Met sheddase Adam-10 triggered auto-phosphorylation and responsiveness to Hgf. Accordingly, Adam-10 knock down increased Met phosphorylation in metastatic foci and induced tumor cell scattering into the surrounding liver parenchyma. In conclusion, these findings show that tumor cell-derived Timp-1 acts as a positive regulator of the metastatic potential and support the concept that proteases and their natural inhibitors, as members of the protease web, are major players of signaling during normal homeostasis and disease.
Literature
1.
go back to reference Terpos E, Dimopoulos MA, Shrivastava V et al (2010) High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res 34(3):399–402PubMedCrossRef Terpos E, Dimopoulos MA, Shrivastava V et al (2010) High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res 34(3):399–402PubMedCrossRef
2.
go back to reference Aaberg-Jessen C, Christensen K, Offenberg H et al (2009) Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol 95(1):117–128PubMedCrossRef Aaberg-Jessen C, Christensen K, Offenberg H et al (2009) Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival. J Neurooncol 95(1):117–128PubMedCrossRef
3.
go back to reference Scrideli CA, Cortez MA, Yunes JA et al (2010) mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leuk Res 34(1):32–37PubMedCrossRef Scrideli CA, Cortez MA, Yunes JA et al (2010) mRNA expression of matrix metalloproteinases (MMPs) 2 and 9 and tissue inhibitor of matrix metalloproteinases (TIMPs) 1 and 2 in childhood acute lymphoblastic leukemia: potential role of TIMP1 as an adverse prognostic factor. Leuk Res 34(1):32–37PubMedCrossRef
4.
go back to reference Rauvala M, Puistola U, Turpeenniemi-Hujanen T (2005) Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99(3):656–663PubMedCrossRef Rauvala M, Puistola U, Turpeenniemi-Hujanen T (2005) Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99(3):656–663PubMedCrossRef
5.
go back to reference Chirco R, Liu XW, Jung KK et al (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25(1):99–113PubMedCrossRef Chirco R, Liu XW, Jung KK et al (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25(1):99–113PubMedCrossRef
6.
go back to reference Mook OR, Frederiks WM, Van Noorden CJ (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705(2):69–89PubMed Mook OR, Frederiks WM, Van Noorden CJ (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 1705(2):69–89PubMed
7.
go back to reference Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174PubMedCrossRef Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174PubMedCrossRef
8.
go back to reference Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564):2387–2392PubMedCrossRef Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295(5564):2387–2392PubMedCrossRef
9.
go back to reference Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34PubMedCrossRef Deryugina EI, Quigley JP (2006) Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25(1):9–34PubMedCrossRef
10.
go back to reference Gutierrez-Fernandez A, Fueyo A, Folgueras AR et al (2008) Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 68(8):2755–2763PubMedCrossRef Gutierrez-Fernandez A, Fueyo A, Folgueras AR et al (2008) Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 68(8):2755–2763PubMedCrossRef
11.
go back to reference Garg P, Sarma D, Jeppsson S et al (2010) Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res 70(2):792–801PubMedCrossRef Garg P, Sarma D, Jeppsson S et al (2010) Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res 70(2):792–801PubMedCrossRef
12.
go back to reference Krüger A et al (2001) Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61(4):1272–1275PubMed Krüger A et al (2001) Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61(4):1272–1275PubMed
13.
go back to reference Schelter F, Halbgewachs B, Baumler P et al (2011) Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1alpha. Clin Exp Metastasis 28(2):91–99PubMedCrossRef Schelter F, Halbgewachs B, Baumler P et al (2011) Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1alpha. Clin Exp Metastasis 28(2):91–99PubMedCrossRef
14.
go back to reference Kopitz C, Gerg M, Bandapalli OR et al (2007) Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67(18):8615–8623PubMedCrossRef Kopitz C, Gerg M, Bandapalli OR et al (2007) Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res 67(18):8615–8623PubMedCrossRef
15.
go back to reference Krüger A (2009) Functional genetic mouse models: promising tools for investigation of the proteolytic internet. Biol Chem 390(2):91–97PubMedCrossRef Krüger A (2009) Functional genetic mouse models: promising tools for investigation of the proteolytic internet. Biol Chem 390(2):91–97PubMedCrossRef
16.
go back to reference Overall CM, Kleifeld O (2006) Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6(3):227–239PubMedCrossRef Overall CM, Kleifeld O (2006) Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6(3):227–239PubMedCrossRef
17.
go back to reference Krüger A, Kates RE, Edwards DR (2010) Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 1803(1):95–102PubMedCrossRef Krüger A, Kates RE, Edwards DR (2010) Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochim Biophys Acta 1803(1):95–102PubMedCrossRef
18.
go back to reference Gerg M, Kopitz C, Schaten S et al (2008) Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases. Mol Cancer Res 6(3):341–351PubMedCrossRef Gerg M, Kopitz C, Schaten S et al (2008) Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases. Mol Cancer Res 6(3):341–351PubMedCrossRef
19.
go back to reference Schelter F, Gerg M, Halbgewachs B et al (2010) Identification of a survival-independent metastasis-enhancing role of hypoxia-inducible factor-1alpha with a hypoxia-tolerant tumor cell line. J Biol Chem 285(34):26182–26189PubMedCrossRef Schelter F, Gerg M, Halbgewachs B et al (2010) Identification of a survival-independent metastasis-enhancing role of hypoxia-inducible factor-1alpha with a hypoxia-tolerant tumor cell line. J Biol Chem 285(34):26182–26189PubMedCrossRef
20.
go back to reference Naldini L, Weidner KM, Vigna E et al (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10(10):2867–2878PubMed Naldini L, Weidner KM, Vigna E et al (1991) Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 10(10):2867–2878PubMed
21.
go back to reference Boccaccio C, Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6(8):637–645PubMedCrossRef Boccaccio C, Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6(8):637–645PubMedCrossRef
22.
go back to reference Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11(12):834–848PubMedCrossRef Trusolino L, Bertotti A, Comoglio PM (2010) MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 11(12):834–848PubMedCrossRef
23.
go back to reference Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7(6):504–516PubMedCrossRef Comoglio PM, Giordano S, Trusolino L (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7(6):504–516PubMedCrossRef
24.
go back to reference Murphy G (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8(12):929–941PubMedCrossRef Murphy G (2008) The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 8(12):929–941PubMedCrossRef
25.
go back to reference Amour A, Knight CG, Webster A et al (2000) The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 473(3):275–279PubMedCrossRef Amour A, Knight CG, Webster A et al (2000) The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 473(3):275–279PubMedCrossRef
26.
go back to reference Schelter F, Kobuch J, Moss ML et al (2010) A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem 285(34):26335–26340PubMedCrossRef Schelter F, Kobuch J, Moss ML et al (2010) A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. J Biol Chem 285(34):26335–26340PubMedCrossRef
27.
go back to reference Schirrmeister W, Gnad T, Wex T et al (2009) Ectodomain shedding of E-cadherin and c-Met is induced by Helicobacter pylori infection. Exp Cell Res 315(20):3500–3508PubMedCrossRef Schirrmeister W, Gnad T, Wex T et al (2009) Ectodomain shedding of E-cadherin and c-Met is induced by Helicobacter pylori infection. Exp Cell Res 315(20):3500–3508PubMedCrossRef
28.
go back to reference Koshariya M, Jagad RB, Kawamoto J et al (2007) An update and our experience with metastatic liver disease. Hepatogastroenterology 54(80):2232–2239PubMed Koshariya M, Jagad RB, Kawamoto J et al (2007) An update and our experience with metastatic liver disease. Hepatogastroenterology 54(80):2232–2239PubMed
30.
31.
go back to reference Krüger A, Schirrmacher V, von Hoegen P (1994) Scattered micrometastases visualized at the single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cells. Int J Cancer 58(2):275–284PubMedCrossRef Krüger A, Schirrmacher V, von Hoegen P (1994) Scattered micrometastases visualized at the single-cell level: detection and re-isolation of lacZ-labeled metastasized lymphoma cells. Int J Cancer 58(2):275–284PubMedCrossRef
32.
go back to reference Soneoka Y, Cannon PM, Ramsdale EE et al (1995) A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 23(4):628–633PubMedCrossRef Soneoka Y, Cannon PM, Ramsdale EE et al (1995) A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 23(4):628–633PubMedCrossRef
33.
go back to reference Krüger A, Schirrmacher V, Khokha R (1998) The bacterial lacZ gene: an important tool for metastasis research and evaluation of new cancer therapies. Cancer Metastasis Rev 17(3):285–294PubMedCrossRef Krüger A, Schirrmacher V, Khokha R (1998) The bacterial lacZ gene: an important tool for metastasis research and evaluation of new cancer therapies. Cancer Metastasis Rev 17(3):285–294PubMedCrossRef
34.
go back to reference Schrötzlmair F, Kopitz C, Halbgewachs B et al (2010) Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. J Cell Mol Med 14(12):2760–2770PubMedCrossRef Schrötzlmair F, Kopitz C, Halbgewachs B et al (2010) Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator. J Cell Mol Med 14(12):2760–2770PubMedCrossRef
35.
go back to reference Brand K et al (2000) Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 60(20):5723–5730PubMed Brand K et al (2000) Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 60(20):5723–5730PubMed
36.
go back to reference Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115(Pt 19):3719–3727PubMedCrossRef Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115(Pt 19):3719–3727PubMedCrossRef
37.
go back to reference Bajou K et al (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4(8):923–928PubMedCrossRef Bajou K et al (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4(8):923–928PubMedCrossRef
38.
go back to reference Krüger A, Fata JE, Khokha R (1997) Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90(5):1993–2000PubMed Krüger A, Fata JE, Khokha R (1997) Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 90(5):1993–2000PubMed
39.
go back to reference Elezkurtaj S, Kopitz C, Baker AH et al (2004) Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. J Gene Med 6(11):1228–1237PubMedCrossRef Elezkurtaj S, Kopitz C, Baker AH et al (2004) Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. J Gene Med 6(11):1228–1237PubMedCrossRef
40.
go back to reference Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803(1):55–71PubMedCrossRef Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803(1):55–71PubMedCrossRef
41.
go back to reference Foveau B et al (2009) Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 20(9):2495–2507PubMedCrossRef Foveau B et al (2009) Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 20(9):2495–2507PubMedCrossRef
42.
go back to reference Amour A et al (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435(1):39–44PubMedCrossRef Amour A et al (1998) TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 435(1):39–44PubMedCrossRef
43.
go back to reference Moss ML, Stoeck A, Yan W et al (2008) ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol 9(1):2–8PubMedCrossRef Moss ML, Stoeck A, Yan W et al (2008) ADAM10 as a target for anti-cancer therapy. Curr Pharm Biotechnol 9(1):2–8PubMedCrossRef
44.
go back to reference Würtz SO, Schrohl AS, Sorensen NM et al (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12(2):215–227PubMedCrossRef Würtz SO, Schrohl AS, Sorensen NM et al (2005) Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12(2):215–227PubMedCrossRef
Metadata
Title
Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10
Authors
Florian Schelter
Martina Grandl
Bastian Seubert
Susanne Schaten
Stephanie Hauser
Michael Gerg
Carla Boccaccio
Paolo Comoglio
Achim Krüger
Publication date
01-12-2011
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 8/2011
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-011-9410-z

Other articles of this Issue 8/2011

Clinical & Experimental Metastasis 8/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine